PolyPeptide Group
PPGN.SWPre-clinicalPolyPeptide is a world-leading CDMO for peptide APIs, leveraging over 70 years of experience since its founding in 1952. The company has manufactured over 1,000 peptides in GMP quality and serves a fast-growing market, particularly in metabolic diseases like diabetes and obesity. As a publicly traded company on the SIX Swiss Exchange, it maintains a broad project pipeline and is investing in capacity expansion to meet future demand.
PPGN.SW · Stock Price
Historical price data
AI Company Overview
PolyPeptide is a world-leading CDMO for peptide APIs, leveraging over 70 years of experience since its founding in 1952. The company has manufactured over 1,000 peptides in GMP quality and serves a fast-growing market, particularly in metabolic diseases like diabetes and obesity. As a publicly traded company on the SIX Swiss Exchange, it maintains a broad project pipeline and is investing in capacity expansion to meet future demand.
Technology Platform
End-to-end peptide API development and manufacturing platform, encompassing pre-GMP process development, custom research-grade synthesis, GMP-compliant solid-phase and solution-phase peptide synthesis, purification, lyophilization, and radiolabeling.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Primary competitors include other pure-play peptide CDMOs like Bachem and AmbioPharm, as well as diversified CDMOs with peptide capabilities such as CordenPharma and Piramal Pharma Solutions. PolyPeptide differentiates through its 70+ year heritage, exclusive peptide focus, global GMP network, and track record of manufacturing over 1,000 GMP peptides.
Company Info
Trading
Contact
Therapeutic Areas
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile